TY - JOUR T1 - Age-structured non-pharmaceutical interventions for optimal control of COVID-19 epidemic JF - medRxiv DO - 10.1101/2020.06.23.20138099 SP - 2020.06.23.20138099 AU - Quentin Richard AU - Samuel Alizon AU - Marc Choisy AU - Mircea T. Sofonea AU - Ramsès Djidjou-Demasse Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/26/2020.06.23.20138099.abstract N2 - In an epidemic, individuals can widely differ in the way they spread the infection depending on their age or on the number of days they have been infected for. In the absence of pharmaceutical interventions such as a vaccine or treatment, non-pharmaceutical interventions (e.g. social distancing) are essential to mitigate the pandemic. We develop an original approach to identify the optimal age-stratified control strategy to implement as a function of the time since the onset of the epidemic. This is based on a model with a double continuous structure in terms of host age and time since infection. By applying optimal control theory to this model, we identify a solution that minimizes deaths and costs associated with the implementation of the control strategy itself. We also implement this strategy to three countries with contrasted age distributions (Burkina-Faso, France, and Vietnam). Overall, the optimal strategy varies over the course of the epidemic, with a more intense control early on, and depending on host age, with a stronger control for the older population, except in the scenario where the cost associated with the control is low. In the latter scenario, we find strong differences across countries because the control extends to younger population in France and Vietnam 2-3 months after the onset of the epidemic, but not in Burkina Faso. Finally, we show that the optimal control strategy strongly outperforms constant uniform control of the whole population or over its younger fraction. This better understanding of the effect of age-based control interventions opens new perspectives for the field, especially for age-based contact tracing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data pertaining to this study are available within the manuscript ER -